MEP19408A - Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same - Google Patents
Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the sameInfo
- Publication number
- MEP19408A MEP19408A MEP-194/08A MEP19408A MEP19408A ME P19408 A MEP19408 A ME P19408A ME P19408 A MEP19408 A ME P19408A ME P19408 A MEP19408 A ME P19408A
- Authority
- ME
- Montenegro
- Prior art keywords
- compositions
- active ingredient
- preparing
- biodegradable polymer
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229920002988 biodegradable polymer Polymers 0.000 title abstract 2
- 239000004621 biodegradable polymer Substances 0.000 title abstract 2
- 239000003420 antiserotonin agent Substances 0.000 title 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 239000006104 solid solution Substances 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000007580 dry-mixing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
Nova klasa biorazgradivih farmaceutskih kompozicija korisnih kao ljekovite kompozicije sa kontinualnim oslobađanjem, uključujući postupke njihovog dobijanja i primjene ovih preparata, kako je opisano i zahtjevano. Postupak dobijanja ovih kompozicija uključuje faze: a) suvog mješanja farmaceutski aktivnog molekula sa biorazgradivim polimerom; b) ekstrudovanja rastopa smješe radi formiranja čvrstog rastvora aktivnog molekula u polimeru; i c) granulacije čvrstog rastvora radi formiranja mikročestica tako da se mogu dobiti injektibiIne formulacije. Poželjne realizacije uključuju farmaceutske kompozicije polilaktid-ko-glikolida i (+)-α-(2,3-dimetoksifenil)-1 -(2-(4-fluorofenif)etil)-4-piperidinmetanola (aktivni sastojak) i postupak za njihovo dobijanje. Ove kompozicije oslobađaju aktivni sastojak ravnomjernom brzinom u toku nekoliko dana do nekoliko nedelja. Aktivni sastojak antagonizuje efekte serotonina na 5HT2A receptor i koristan je u tretiranju različitih poremećaja kao, na primjer, psihoze uključujući šizofreniju, opsesivno kompulsivni poremećaj, poremećaj spavanja, depresiju, anoreksiju, anksioznost, bolesti zavisnosti i bipolarni proremećaji.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21298698A | 1998-12-16 | 1998-12-16 | |
| PCT/US1999/027705 WO2000035423A1 (en) | 1998-12-16 | 1999-11-22 | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| YUP-414/01A RS50123B (sr) | 1998-12-16 | 1999-11-22 | Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP19408A true MEP19408A (en) | 2010-06-10 |
Family
ID=22793267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-194A ME00066B (me) | 1998-12-16 | 1999-11-22 | Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja |
| MEP-194/08A MEP19408A (en) | 1998-12-16 | 1999-11-22 | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-194A ME00066B (me) | 1998-12-16 | 1999-11-22 | Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1140026B1 (bs) |
| JP (1) | JP4759141B2 (bs) |
| KR (1) | KR100707710B1 (bs) |
| CN (1) | CN1195497C (bs) |
| AP (1) | AP1769A (bs) |
| AR (1) | AR021652A1 (bs) |
| AT (1) | ATE303795T1 (bs) |
| AU (1) | AU770673B2 (bs) |
| BG (1) | BG65500B1 (bs) |
| BR (1) | BR9916276A (bs) |
| CA (1) | CA2355077C (bs) |
| CR (1) | CR6424A (bs) |
| CZ (1) | CZ301947B6 (bs) |
| DE (1) | DE69927177T2 (bs) |
| DK (1) | DK1140026T3 (bs) |
| EA (1) | EA004502B1 (bs) |
| EE (1) | EE200100314A (bs) |
| ES (1) | ES2245128T3 (bs) |
| HK (1) | HK1041645B (bs) |
| HR (1) | HRP20010446A2 (bs) |
| HU (1) | HU226586B1 (bs) |
| ID (1) | ID28909A (bs) |
| IL (2) | IL143761A0 (bs) |
| ME (2) | ME00066B (bs) |
| NO (1) | NO20012981L (bs) |
| NZ (1) | NZ511962A (bs) |
| OA (1) | OA11728A (bs) |
| PL (1) | PL196822B1 (bs) |
| RS (1) | RS50123B (bs) |
| SK (1) | SK285812B6 (bs) |
| TR (1) | TR200101759T2 (bs) |
| TW (1) | TWI221418B (bs) |
| UA (1) | UA73101C2 (bs) |
| WO (1) | WO2000035423A1 (bs) |
| ZA (1) | ZA200104899B (bs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10061932A1 (de) * | 2000-12-13 | 2002-10-24 | Pharmatech Gmbh | Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion |
| AU2002256694A1 (en) * | 2001-03-20 | 2002-10-03 | Euroscreen S.A. | Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor |
| CZ20033160A3 (en) * | 2001-05-23 | 2004-03-17 | Hexal Ag | Implant manufacturing process by means of solvent free preparation of a homogenate |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| JP5081622B2 (ja) * | 2004-09-21 | 2012-11-28 | 山▲東緑▼叶制▲薬▼有限公司 | ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8377453B2 (en) | 2008-03-11 | 2013-02-19 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| JP5539991B2 (ja) * | 2008-09-18 | 2014-07-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | ポリ（ε−カプロラクトン）を含む医薬剤形 |
| US20100291214A1 (en) * | 2008-12-23 | 2010-11-18 | Armark Authentication Technologies, Llc | Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| WO2010151746A2 (en) * | 2009-06-26 | 2010-12-29 | Armark Authentication Technologies, Llc | Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US20160193151A1 (en) * | 2015-01-06 | 2016-07-07 | Maria Del Pilar Noriega Escobar | Dosage form incorporating an amorphous drug solid solution |
| CN114901064B (zh) * | 2019-12-31 | 2024-03-08 | 万卡坦卡有限公司 | 延长释放塑料配方 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| CH679207A5 (bs) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| US5439688A (en) * | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
| EP0528978B1 (en) * | 1990-05-16 | 2002-10-16 | Southern Research Institute | Mikrocaspules for controlled release and their use to stimulate nerve fiber growth |
| AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
| GB9016885D0 (en) * | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
| AU1537292A (en) * | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| US5505963A (en) * | 1993-04-07 | 1996-04-09 | Schwartz Pharma Ag | Slow release pharmaceutical preparation |
| US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
| BR9509985A (pt) * | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solução para irrigação e método para inibição de dor inflamação e esparmo |
-
1999
- 1999-11-22 IL IL14376199A patent/IL143761A0/xx active IP Right Grant
- 1999-11-22 CN CNB998145831A patent/CN1195497C/zh not_active Expired - Fee Related
- 1999-11-22 RS YUP-414/01A patent/RS50123B/sr unknown
- 1999-11-22 ID IDW00200101296A patent/ID28909A/id unknown
- 1999-11-22 OA OA1200100150A patent/OA11728A/en unknown
- 1999-11-22 ME MEP-2008-194A patent/ME00066B/me unknown
- 1999-11-22 EE EEP200100314A patent/EE200100314A/xx unknown
- 1999-11-22 EA EA200100551A patent/EA004502B1/ru not_active IP Right Cessation
- 1999-11-22 AT AT99960556T patent/ATE303795T1/de active
- 1999-11-22 DK DK99960556T patent/DK1140026T3/da active
- 1999-11-22 HK HK02103401.5A patent/HK1041645B/zh not_active IP Right Cessation
- 1999-11-22 AP APAP/P/2001/002198A patent/AP1769A/en active
- 1999-11-22 ES ES99960556T patent/ES2245128T3/es not_active Expired - Lifetime
- 1999-11-22 HU HU0105048A patent/HU226586B1/hu not_active IP Right Cessation
- 1999-11-22 BR BR9916276-8A patent/BR9916276A/pt not_active Application Discontinuation
- 1999-11-22 KR KR1020017007561A patent/KR100707710B1/ko not_active Expired - Fee Related
- 1999-11-22 TR TR2001/01759T patent/TR200101759T2/xx unknown
- 1999-11-22 CA CA002355077A patent/CA2355077C/en not_active Expired - Fee Related
- 1999-11-22 DE DE69927177T patent/DE69927177T2/de not_active Expired - Lifetime
- 1999-11-22 HR HR20010446A patent/HRP20010446A2/hr not_active Application Discontinuation
- 1999-11-22 NZ NZ511962A patent/NZ511962A/xx not_active IP Right Cessation
- 1999-11-22 JP JP2000587744A patent/JP4759141B2/ja not_active Expired - Fee Related
- 1999-11-22 CZ CZ20012157A patent/CZ301947B6/cs not_active IP Right Cessation
- 1999-11-22 AU AU17425/00A patent/AU770673B2/en not_active Ceased
- 1999-11-22 WO PCT/US1999/027705 patent/WO2000035423A1/en not_active Ceased
- 1999-11-22 ME MEP-194/08A patent/MEP19408A/xx unknown
- 1999-11-22 EP EP99960556A patent/EP1140026B1/en not_active Expired - Lifetime
- 1999-11-22 PL PL348233A patent/PL196822B1/pl not_active IP Right Cessation
- 1999-11-22 UA UA2001064165A patent/UA73101C2/uk unknown
- 1999-11-22 SK SK828-2001A patent/SK285812B6/sk not_active IP Right Cessation
- 1999-12-10 TW TW088121702A patent/TWI221418B/zh not_active IP Right Cessation
- 1999-12-14 AR ARP990106345A patent/AR021652A1/es unknown
-
2001
- 2001-06-12 BG BG105591A patent/BG65500B1/bg unknown
- 2001-06-14 IL IL143761A patent/IL143761A/en not_active IP Right Cessation
- 2001-06-14 ZA ZA200104899A patent/ZA200104899B/en unknown
- 2001-06-15 NO NO20012981A patent/NO20012981L/no not_active Application Discontinuation
- 2001-07-16 CR CR6424A patent/CR6424A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200100551A1 (ru) | Антагонист рецептора серотонина, капсулированный биоразлагаемым полимером, и способ его получения | |
| IS7891A (is) | Skiptitengd þrísýklísk gamma-karbólín sem serótónín viðtaka gerandefni og mótverkunarefni | |
| CN1025150C (zh) | 能延续释放的新药物制剂的制备方法 | |
| US5616575A (en) | Bioactive tricyclic ibogaine analogs | |
| KR880001288A (ko) | 경구투여 형태의 서방성 약제학적 조성물 | |
| CA2474698A1 (en) | Polymer-based compositions for sustained release | |
| BG102254A (en) | Oral fast soluble compositions as dopamine antagonists | |
| RU99117926A (ru) | Лекарственные формы и способ лечения расстройства мужской эректильной функции | |
| CN1032490A (zh) | 新药物制剂及其制备方法 | |
| FR2724384B1 (fr) | Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| WO2006032202A1 (fr) | Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation | |
| RU2006147244A (ru) | Способ составления быстро диспергируемых лекарственных форм, содержащих по меньшей мере один рыбий желатин, который выбирают на основе молекулярной массы | |
| Chen et al. | Inflammation‐Responsive Functional Core–Shell Micro‐Hydrogels Promote Rotator Cuff Tendon‐To‐Bone Healing by Recruiting MSCs and Immuno‐Modulating Macrophages in Rats | |
| Priyanka et al. | Formulation and evaluation of gel loaded with microspheres of apremilast for transdermal delivery system | |
| EP0759299A1 (en) | Potentiation of serotonin response | |
| CN102579365B (zh) | 利培酮微球制剂及其制备方法 | |
| CN116459220A (zh) | 昔萘酸普拉克索缓释微球及其制备方法与应用 | |
| CN105384676B (zh) | 三重再摄取抑制剂及其应用方法 | |
| UY25864A1 (es) | Derivados de acetamida antagonistas de receptor de nk1 | |
| Foreman et al. | Preclinical studies on LY237733, a potent and selective serotonergic antagonist. | |
| ATE318819T1 (de) | Pyrazinochinoxalin-derivate als serotonin- agonisten und -antagonisten | |
| CA2430707C (en) | 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl]-piperazin-1-yl}-2-methyl-4h-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine d2 receptor and the serotonin reuptake site | |
| EA200700877A1 (ru) | Диспергируемая во рту фармацевтическая композиция и способ ее получения | |
| AU2023366306A1 (en) | Phenethylamine compounds, compositions, and methods of use |